Washington, DC (February 25, 2021) – Healthcare Supply Chain Association (HSCA) President and CEO Khatereh Calleja today released the following statement regarding President Biden’s Executive Order on America’s supply chains of critical goods, products, and services:
“HSCA and its member group purchasing organizations (GPOs) applaud President Biden for his focus on strengthening the resiliency of America’s critical supply chains, including the healthcare supply chain.
“The COVID-19 pandemic has underscored the importance of having a strong and diverse healthcare supply chain to ensure patient and provider access to critical medical products. GPOs have played a critical role in supporting COVID-19 response efforts and have long advocated for policy solutions that promote a robust and redundant supply chain. While we are still reviewing the Executive Order, we thank President Biden for his efforts to support a sustainable supply chain, and we look forward to working with him and his Administration to strengthen supply chain resiliency and preserve access to care.”
Click here to read the full statement.Lear More
HSCA Statement on President Biden’s Executive Order on the Healthcare Supply Chain
Washington, DC (January 22, 2021) – Healthcare Supply Chain Association (HSCA) President and CEO Khatereh Calleja today released the following statement regarding President Biden’s Executive Order on a sustainable public health supply chain:
“HSCA and its member group purchasing organizations (GPOs) applaud President Biden for his focus on ensuring patient and provider access to critical medical supplies.
Click here to read the full release.Lear More
Dear Chairman Alexander and Ranking Member Murray,
As the United States takes steps in response to the outbreak of COVID-19, concerns with the integrity of the drug supply chain and the potential impact on downstream drug shortages have surfaced. While no drug shortages have been reported thus far in direct correlation with COVID-19, past situations such as H1N1, Ebola, and Hurricane Maria have highlighted vulnerabilities in the drug supply chain that require congressional action to ensure a stable supply of critical medications is available for patient care. Furthermore, the World Health Organization (WHO) and the Food and Drug Administration (FDA) have stated the COVID-19 outbreak will likely impact the medical product supply chain, including potential disruptions to supply or shortages of critical medical products in the United States.
Therefore, the undersigned organizations are writing in support of S.2723 – The Mitigating Emergency Drug Shortages (MEDS) Act which is a holistic and sustainable approach to eliminating drugs shortages and addressing vulnerabilities in the drug supply chain. We urge the Senate Committee on Health, Education, Labor, and Pensions (HELP) to advance this critical piece of legislation expeditiously.
Click here to read the full letter.